HGF/c-Met raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-11 and is reviewed periodically as new material appears.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
| Property | Value | Notes |
|---|---|---|
| Primary reported target | Hepatocyte growth factor/c-Met signaling | Findings mainly from cell and animal studies. |
| Related endogenous peptide | Angiotensin IV | Dihexa is described as a stabilized analog. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for purity assessment. |
| Identity confirmation | Mass spectrometry | Provides a molecular mass check. |
| Regulatory status | Not approved for human use | Sold as a research chemical in many jurisdictions. |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
== Discovery == GnIH was discovered in 2000. It is an RFamide peptide that significantly reduced luteinizing hormone release in Coturnix Japonica (Japanese quail). This peptide emerged as the first tropic hormone known to inhibit gonadotropin secretion in the hypothalamic-pituitary-gonadal axis of vertebrates. Subsequent research identified GnIH peptide homologs in variety of mammals, including humans.
The South West Africa People's Organisation (SWAPO ; Afrikaans: Suidwes-Afrikaanse Volks Organisasie, SWAVO; German: Südwestafrikanische Volksorganisation, SWAVO), officially known as the SWAPO Party of Namibia, is a political party and former independence movement in Namibia (formerly South West Africa). Founded in 1960, it has been the governing party in Namibia since the country achieved independence in 1990. The party continues to be dominated in number and influence by the Ovambo ethnic group. SWAPO held a two-thirds majority in parliament from 1994 to 2019. In the general election held in November 2019, the party won 65.5% of the popular vote and 63 out of the 104 seats in the National Assembly. It also holds 28 out of the 42 seats in the National Council. From November 2017 until his death in February 2024, Namibian President Hage Geingob remained the president of SWAPO after being elected to the position at the party's electoral congress.
Delivery of oral high-dose supplements remains the principal strategy for minimizing deficiency. As of 2017, more than 80 countries worldwide are implementing universal VAS programs targeted to children 6–59 months of age through semi-annual national campaigns. Doses in these programs are one dose of 50,000 or 100,000 IU for children aged 6 to 11 months and 100,000 to 200,000 IU for children aged 12 months to five years, every four to six months.
Sources: en.wikipedia.org
=== Flavour and aroma === Dozens of compounds contribute to Scotch whisky flavour and aroma characteristics, including volatile alcohol congeners (also called higher oils) formed during fermentation, such as acetaldehyde, methanol, ethyl acetate, n-propanol and isobutanol. Other flavour and aroma compounds include vanillic acid, syringic acid, vanillin, syringaldehyde, furfural, phenyl ethanol and acetic acid. One analysis established 13 distinct flavour characteristics dependent on individual compounds, including sour, sweet, grainy and floral as major flavour perceptions. Some distilleries use a peat fire to dry the barley for some of their products before grinding it and making the mash. Peat smoke contributes phenolic compounds, such as guaiacol, that give aromas similar to smoke. The Maillard browning process of the residual sugars in the mashing process, particularly through formation of 2-furanmethanol and pyrazines imparting nutty or cereal characteristics contributes to the baked bread notes in the flavour and aroma profile. Maturation during multi-year casking in oak barrels mostly previously used for bourbon whiskey, sherry, wines, fortified wine (including port and Madeira), rum and other spirit production, has the largest impact on the flavour of the whisky. Some distilleries use virgin oak casks as used casks are becoming increasingly harder to source (particularly authentic sherry casks due to the downturn in sherry consumption plus the laws introduced in 1986 regarding bottling Spanish wines exclusively in Spain).
== See also == Estradiol dibutyrate/hydroxyprogesterone heptanoate/testosterone caproate Estradiol diundecylate/hydroxyprogesterone heptanoate/testosterone cyclohexylpropionate Estrapronicate/hydroxyprogesterone heptanoate/nandrolone undecanoate Progesterone/hydroxyprogesterone heptanoate/α-tocopherol palmitate
All meitnerium isotopes are extremely unstable (radioactive); in general, heavier isotopes are more stable than the lighter. The most stable known isotope, 278Mt (half-life 4.5 seconds), is also the heaviest known. The unconfirmed 282Mt is even heavier and seems to have a longer half-life, 67 seconds. With a half-life of 0.8 seconds, the next most stable known isotope is 270Mt. 276Mt and 274Mt have half-lives of 0.62 and 0.64 seconds respectively. 277Mt, created as the final decay product of 293Ts for the first time in 2012, was observed to undergo spontaneous fission, half-life 5 milliseconds. Preliminary data analysis considered the possibility that this fission is instead from 277Hs, for it also has a half-life of a few milliseconds, and could come from undetected electron capture somewhere in the decay chain. This possibility was later deemed very unlikely based on observed decay energies of 281Ds and 281Rg and the short half-life of 277Mt, although there is still some uncertainty of the assignment. Regardless, the rapid fission of 277Mt and 277Hs is strongly suggestive of a region of instability for superheavy nuclei with N = 168–170. The existence of this region, characterized by a decrease in fission barrier height between the deformed shell closure at N = 162 and spherical shell closure at N = 184, is consistent with theoretical models.
Sources: en.wikipedia.org
Heparin-binding EGF-like growth factor (HB-EGF) is a member of the EGF family of proteins that in humans is encoded by the HBEGF gene. HB-EGF-like growth factor is synthesized as a membrane-anchored mitogenic and chemotactic glycoprotein. An epidermal growth factor produced by monocytes and macrophages, due to an affinity for heparin is termed HB-EGF. It has been shown to play a role in wound healing, cardiac hypertrophy, and heart development and function. First identified in the conditioned media of human macrophage-like cells, HB-EGF is an 87-amino acid glycoprotein that displays highly regulated gene expression. Ectodomain shedding results in the soluble mature form of HB-EGF, which influences the mitogenicity and chemotactic factors for smooth muscle cells and fibroblasts. The transmembrane form of HB-EGF is the unique receptor for diphtheria toxin and functions in juxtacrine signaling in cells. Both forms of HB-EGF participate in normal physiological processes and in pathological processes including tumor progression and metastasis, organ hyperplasia, and atherosclerotic disease. HB-EGF can bind two locations on cell surfaces: heparan sulfate proteoglycans and EGF-receptors effecting cell-to-cell interactions.
== SASP Index == A SASP index composed of 22 SASP factors has been used to evaluate treatment outcomes of late life depression. Higher SASP index scores corresponded to increased incidence of treatment failure, whereas no individual SASP factors were associated with treatment failure.
== Bibliography == Christiano, A. M., Greenspan, D. S., Hoffman, G. G., Zhang, X., Tamai, Y., Lin, A.N., Dietz, H.C., Hovnanian, A., & Uitto, J (1993). A missense mutation in type VII collagen in two affected siblings with recessive dystrophic epidermolysis bullosa. Nature Genet. 462–66. Toriello, H. V., Glover, T. W., Takahara, K., Byers, P., Miller, D. E., Higgins, J. V., & Greenspan, D. S. (1996). A translocation interrupt the COL5A1 gene in a patient with Ehlers-Danlos syndrome and hypomelanosis of Ito. Nature Genet 13, 361–365. Kessler, E., Takahara, K., Biniaminov, L., Brusel, M., & Greenspan, D. S. (1996). Bone morphogenetic protein-1: the type I procollagen C-proteinase. Science, 271(5247), 360–362. Clark, T. G., Conway, S. J., Scott, I. C., Labosky, P. A., Winnier, G., Bundy, J., Hogan, B. L. M., & Greenspan, D. S. (1999). The mammalian tolloid-like 1 gene, Tll1, is necessary for normal septation and positioning of the heart. Development 126, 2631–2642. Scott, I. C., Blitz, I. L., Pappano, W. N., Maas, S. A., Cho, K. W. Y., & Greenspan, D. S. (2001). Twisted gastrulation homologs are extracellular cofactors in antagonism of BMP signaling. Nature 410, 475–478. Dart, M. L., Jankowska-Gan, E., Huang, G., Roenneburg, D. A., Keller, M. R., Torrealba, J. R., Rhoads, A., Marshall-Case, S., Kim, B., Bobadilla, J. L., Haynes, L. D., Wilkes, D. S., Burlingham, W. J., & Greenspan, D. S. (2010). IL-17-dependent autoimmunity to collagen type V in atherosclerosis. Circ Res 107, 1106–1116. Huang, G., Ge, G., Wang, D., Gopalakrishnan, B., Butz, D. H., Colman, R.
Another dimension to the tactical use of nuclear weapons is that of such weapons deployed at sea for use against surface and submarine vessels. Until 1992, vessels of the United States Navy (and their aircraft) deployed various such weapons as bombs, rockets (guided and unguided), torpedoes, and depth charges. Such tactical naval nuclear weapons were considered more acceptable to use early in a conflict because there would be few civilian casualties. It was feared by many planners that such use would probably quickly have escalated into a large-scale nuclear war. This situation was particularly exacerbated by the fact that such weapons at sea were not constrained by the safeguards provided by the Permissive Action Link attached to U.S. Air Force and Army nuclear weapons. It is unknown if the navies of the other nuclear powers yet today deploy tactical nuclear weapons at sea. The 2018 US Nuclear Posture Review emphasised the need for the US to have sub-strategic nuclear weapons as additional layers for its nuclear deterrence.
Sources: en.wikipedia.org
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.
Reverse-phase high-performance liquid chromatography is commonly used to assess purity. Mass spectrometry is used to confirm molecular identity. These methods are typical for synthetic peptides and research chemicals.
Dihexa is not approved as a drug in major jurisdictions. It is often sold as a research chemical, which is not the same as a medicine. Its legal status can vary by country and may change.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.